ArticleFrontiers in immunology2026
The prognostic significance of the lactate dehydrogenase-to-albumin ratio in extensive-stage small cell lung cancer patients receiving chemo-immunotherapy: a multicenter study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lactate dehydrogenase-to-albumin ratio (LAR) has been acknowledged as an independent prognostic factor for multiple diseases. However, its prognostic significance in extensive-stage small cell lung cancer (ES-SCLC) patients treated with immune checkpoint inhibitors (ICIs) remains ambiguous. This study aims to explore the influence of LAR on the prognosis of ES-SCLC patients undergoing ICIs combined with chemotherapy. Methods: A cohort of 628 patients with ES-SCLC who received ICIs from five hospitals underwent pre-treatment blood biochemical examinations. The overall survival (OS) and progression-free survival (PFS) were analyzed via Cox regression models and Kaplan-Meier survival curves. A multivariate Cox proportional hazards model was constructed to develop a nomogram based on independent prognostic factors. The predictive performance and clinical utility of the nomogram were evaluated using the area under the time-dependent receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA). Results: LAR was identified as an independent prognostic factor influencing PFS and OS. Compared to low levels of LAR, elevated LAR is associated with shorter OS (HR = 4.97,95% CI: 3.32-7.45, P < 0.001) and PFS (HR = 3.02,95% CI: 2.17-4.21, P < 0.001). The ROC curve for OS prediction in the training set exhibited areas under the curve (AUCs) of 0.833 at 1 year and 0.874 at 2 years, whereas the internal validation set showed AUCs of 0.819 for 1- year OS and 0.891 for 2-year OS. The AUCs for 1-year PFS and 2-year PFS in the training set were 0.842 and 0.889, respectively, compared to 0.799 and 0.921 in the internal validation set. Calibration curves verified a good concordance between predicted and observed outcomes in both the training and internal validation sets. In the independent external test cohort, the calibration curve also demonstrated consistency between predicted and observed results. The AUCs for 1-year OS and 2-year OS in the external test set were 0.76 and 0.69. The AUCs for 1-year PFS and 2-year PFS in the external test set were 0.59 and 0.58. Conclusion: In patients with ES-SCLC receiving ICIs combined with chemotherapy, a high pre-treatment LAR was associated with worse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.